Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $173 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma (ASND) and maintained a $173 price target. This reaffirms the firm's positive outlook on the company's stock.
April 01, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma and maintained a $173 price target, indicating a positive outlook on the stock.
The reiteration of an Overweight rating and the maintenance of a high price target ($173) by a reputable analyst firm like Cantor Fitzgerald suggests a strong vote of confidence in Ascendis Pharma's stock. This is likely to positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100